If You Invested in Humacyte, Inc. Warrant (HUMAW)
See the HUMAW overviewWhat $1,000 or $10,000 in HUMAW Was Worth at Its Last Close
Real historical value by amount invested and how long before the last close| If you invested | 1 year before | 5 years before | 10 years before | Since Aug 27, 2021 |
|---|---|---|---|---|
| $1,000 | $4.86 -99.51% | — | — | $0.30 -99.97% |
| $10,000 | $49 -99.51% | — | — | $3.00 -99.97% |
Based on real historical closing prices adjusted for stock splits, without dividends, through 2026-08-25. Figures with dividends reinvest each cash dividend at the previous close less the dividend, before taxes. Past performance does not guarantee future results.
Custom Calculation
Choose your own date and amount for HUMAW$1,000 Investment Over Time
HUMAW vs S&P 500Year-by-Year Returns
HUMAW annual performance| Year | Start Price | End Price | Annual Return | Cumulative |
|---|---|---|---|---|
| 2021Aug 27, 2021 to Dec 31, 2021 | $3.00 | $2.28 | -24.0% | -24.0% |
| 2022 | $2.28 | $0.3926 | -82.8% | -86.9% |
| 2023 | $0.3926 | $0.4159 | +5.9% | -86.1% |
| 2024 | $0.4159 | $1.82 | +337.6% | -39.3% |
| 2025 | $1.82 | $0.0937 | -94.9% | -96.9% |
| 2026Dec 31, 2025 to Aug 25, 2026 | $0.0937 | $0.0009 | -99.0% | -99.97% |
About Humacyte, Inc. Warrant
NASDAQ
Humacyte, Inc. is a biotechnology company that is developing a biotechnology platform intended to deliver universally implantable bioengineered human tissues and organs. According to available information, these bioengineered materials are designed to improve the lives of patients and support advances in the practice of medicine. The company is associated with the ticker symbol HUMAW on The Nasdaq Stock Market LLC for its redeemable warrants, each whole warrant being exercisable for one share of Humacyte common stock at a specified exercise price.
Humacyte focuses on the development and manufacture of acellular tissues. These tissues are described as being used to treat a range of diseases, injuries, and chronic conditions. The company’s stated pipeline includes areas such as vascular trauma, peripheral arterial disease (PAD), dialysis, acellular tissue engineered vessels, organ systems, and advanced tissue constructs. This pipeline description highlights the company’s emphasis on vascular and tissue-engineered applications within the broader biological products sector.
In regulatory filings, Humacyte identifies itself as an emerging growth company under applicable U.S. securities regulations. The company has entered into financing arrangements, including a Revenue Interest Purchase Agreement and subsequent amendments, to support its activities. These arrangements involve Humacyte, its wholly owned subsidiary Humacyte Global, Inc., and institutional purchasers, and they outline repayment terms, restricted cash requirements, and an option for the company to repurchase certain revenue interests under defined conditions.
Humacyte’s securities structure includes redeemable warrants that are listed on Nasdaq under the symbol HUMAW. These warrants are tied to Humacyte’s common stock and are exercisable at a stated exercise price per share. The presence of these listed warrants provides a way for market participants to gain exposure to Humacyte’s equity through warrant instruments, subject to the terms and conditions set out in the company’s offering and governing agreements.
According to SEC filings, Humacyte has used revenue interest financing, where investors receive payments based on specified revenue-related terms. Amendments to these agreements have addressed matters such as partial repayment amounts, the level of restricted cash to be maintained for the benefit of the financing agent, and the terms under which Humacyte may exercise a call option to repurchase the revenue interests at a defined repurchase price, with a portion of that amount potentially payable in shares of the company’s common stock if certain conditions are satisfied.
Humacyte’s work with acellular tissue engineered vessels and advanced tissue constructs places it within the biological products sector, with a focus on products that are intended to be implanted into patients. The company’s stated goal of creating universally implantable tissues and organs suggests an approach aimed at reducing or eliminating the need for patient-specific donor tissues, although specific clinical or commercial details are not provided in the available summary information.
Humacyte, Inc. is based in Durham, North Carolina. Its regulatory disclosures, including current reports on Form 8-K, provide information on material agreements and financial obligations related to its financing structure. These filings are a primary source for understanding the company’s capital arrangements, warrant terms, and status as an emerging growth company under U.S. securities laws.
Similar Stocks
See how related companies performed
Frequently Asked Questions
Humacyte, Inc. Warrant investment returns
How much was $1,000 invested in Humacyte, Inc. Warrant worth at its last close?
If you invested $1,000 in Humacyte, Inc. Warrant (HUMAW) 1 year before its last close, on 2025-08-25, your investment was worth $4.86 on 2026-08-25, a -99.5% price return without dividends, growing at a compounded rate of -99.5% per year (CAGR).
Has Humacyte, Inc. Warrant outperformed the S&P 500?
Comparison data requires at least 10 years of trading history. Use the calculator above to compare HUMAW performance over available time periods.
What is Humacyte, Inc. Warrant's average annual return?
The compound annual growth rate (CAGR) of HUMAW’s share price over the 1 year to Aug 25, 2026 is -99.5%, without dividends. Individual years vary a great deal, and HUMAW’s best recent full year was 2024 (+337.6%) while the worst was 2025 (-94.9%).
For informational and educational purposes only, not investment advice.
